@article{5bd4806728624f97ac32685ee06392cf,
title = "Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia",
author = "Hovingh, {G. Kees} and Klausen, {Ib Christian} and Eli Heggen and Kevin McCarty and Rong Zhou and Isaac, {Barton F.} and Rebecca Taub and Gisle Langslet and Kastelein, {John J. P.}",
note = "Funding Information: This study was sponsored by Madrigal Pharmaceuticals. The sponsor was involved in the study design and collection, analysis, and interpretation of data as well as data checking of information provided in the manuscript. The authors had unrestricted access to study data, were responsible for all content and editorial decisions, and received no honoraria related to the development of this publication. Dr Hovingh is a part-time employee and shareholder of Novo Nordisk (Copenhagen, Denmark). Drs Isaac and Taub are employees and shareholders of Madrigal Pharmaceuticals. Dr Langslet has received lecture and advisory board fees from Amgen, Sanofi, and Boehringer Ingelheim. Dr Kastelein has received personal fees from AstraZeneca, CiVi Biopharma, CSL Behring, Draupnir, Esperion, Madrigal Pharmaceuticals, Matinas Biopharma, North Sea Therapeutics, Novo Nordisk, Novartis, Regeneron, RegenXBio, SirnaOmics, Staten Biotech, 89 Bio, and Omeicos; and is part-time employee of NewAmsterdam Pharma. The authors thank the participants, their families, and investigators involved in this study. (Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia; NCT03038022 )",
year = "2022",
month = mar,
day = "29",
doi = "https://doi.org/10.1016/j.jacc.2022.01.023",
language = "English",
volume = "79",
pages = "1220--1222",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "12",
}